Bruce Rehlaender Formulation Development Expert in bioavailability optimization, formulation of poorly soluble drugs, lyophilized product development, and particle size analysis.

Dr. Rehlaender has over 20 years experience in pharmaceutical research and development, primarily in the arena of formulation development. He has worked with both small and large molecules and has developed products for oral, parenteral, topical, pulmonary, intranasal, and intrauterine delivery. His areas of expertise include bioavailability optimization, formulation of poorly soluble drugs, lyophilized product development, and particle size analysis.

Prior to joining PharmaDirections, Dr. Rehlaender headed up the Formulations Group at Cirrus Pharmaceuticals, an intellect-rich CRO focused on formulation development. Earlier he worked as a formulations scientist for Pharmacia and Upjohn. He holds a bachelors degree in biochemistry from UC Berkeley and a Ph.D. in pharmaceutical sciences from UNC Chapel Hill. Dr. Rehlaender’s dissertation research focused on the effects of monovalent antibody binding on drug pharmacokinetics. In addition to formulation development, Dr. Rehlaender has extensive experience in process development, including lyophilization and sterilization cycle development, and in manufacturing of clinical and commercial drug products.